Sex differences in cardiovascular outcomes of SGLT-2 inhibitors in heart failure randomized controlled trials: A systematic review and meta-analysis

Resource type: Publication Publication
  • Authors
    Rivera F.; Golbin J.M.; Ansay M.F.M.; Rocimo A.M.R.; Alfonso P.G.I.; Ong B.A.G.; Talino M.K.; De Luna D.; McCullough P.A.; Volgman A.S.
  • Type
    Original Research
  • Journal
    Circulation
  • Publication Date
    2022
  • Abstract

    Randomized controlled trials of sodium-glucose transporter-2 inhibitors (SGLT-2is) have proven to be effective in decreasing major adverse cardiovascular events (MACE) in patients with heart failure. A recently published meta-analysis showed that the use of SGLT-2i among women with diabetes resulted in less reduction in MACE vs. men. This study aims to determine sex differences in MACE in patients with chronic heart failure.

Access Publication

Related News